about
Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's DiseaseCase-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortiumAttainment of peak bone mass at the lumbar spine, femoral neck and radius in men and women: relative contributions of bone size and volumetric bone mineral density.Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.Accuracy and precision of peripheral quantitative computed tomography measurements at the tibial metaphysis.FRAX®: prediction of major osteoporotic fractures in women from the general population: the OPUS study.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.The effect of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia.Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritisDiagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.Biochemical markers of bone turnover.Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.Preanalytical variability of biochemical markers of bone turnover.Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state.Heart drugs that affect bone.Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.Diet and healthy bones.Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density.Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatideLeptin may play a role in bone microstructural alterations in obese children.Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.Prediction of incident hip fracture with the estimated femoral strength by finite element analysis of DXA Scans in the study of osteoporotic fractures.Effect of stopping risedronate after long-term treatment on bone turnover.Growth in infancy and bone mass in later lifeRole of oestrogen in the regulation of bone turnover at the menarche.Identification of vertebral fractures: an update.Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.Lipid profiles within the SABRE trial of anastrozole with and without risedronate.Long-term effects of aromatase inhibitors on bone.The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).Potential role of pancreatic and enteric hormones in regulating bone turnover.International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonatesDistribution of bone density in the proximal femur and its association with hip fracture risk in older men: the osteoporotic fractures in men (MrOS) study.Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trialMeasurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.
P50
Q28115466-6247085B-5465-4A96-8B79-1CB7CADF526BQ30240109-148626BB-D793-4C92-80A4-56F575FA8AD8Q30579240-4FE31451-DBB9-4D01-8A86-7F8126396789Q31051097-E8BA8B67-919F-4279-8624-387DF64D22BFQ31065032-711643B6-3E96-408B-B2DC-C1DE31EDC3C0Q31072660-22B4E811-352B-40A3-B548-015A0CAEB172Q31147039-D7216A76-5D25-4B7F-BF0F-DDA51F56F76DQ31921266-604BFAB8-27C4-4506-8D02-BB215486C3D4Q33515447-E9DE5860-F07B-439F-B324-0E4C7E4E84F0Q33578392-846CF316-3D0F-4276-BD20-CF18CCED4BF3Q33707143-38A9F516-8EC3-400D-BD28-3AC487ED66D0Q33734895-0086CA39-82FE-4C08-B970-12BDA97E01B3Q33814283-46035CFE-38FD-481A-BECD-6B55328DC524Q34021807-7A6D95AD-401F-4FDF-8EDE-54A15D90158BQ34148384-A78E0F12-9955-48EE-9891-168D11D0C4BFQ34148390-9A4492E2-C3A9-401B-84F2-6FEEB18F32B0Q34171858-8B6684FD-941F-417B-8400-1C155A318091Q34237726-C1F5AF51-A455-4D24-9085-FD7E89238159Q34415758-17D0B1ED-77ED-4D60-80D0-DD676E86E054Q34435319-7E9B3DF8-229F-4E99-ABF2-168370B4623FQ34548650-18C01556-842A-48FD-9A35-E0B49B123A2BQ34605062-C8A59C73-A274-4A33-98AD-A748A4E0B9EEQ34881765-E1C4EE25-710D-4495-905C-4A33C1BC97AFQ34975945-59CAA564-0221-48C5-9416-6448136DD661Q35055071-B5B9D7E6-D7A8-4C67-8A23-D7614B10FC4BQ35215353-0942B7D4-A86E-49B8-B05C-123780E448BDQ35299652-BD943F89-6966-482A-87CB-9515E331ABCEQ35498057-36176F4B-0860-43F1-84EE-DC1C079791BCQ35546890-84CEF17C-E1B5-4611-8899-AE9668BAE604Q36104307-3A61F8E8-81BD-496B-ABBC-704EAD0A6475Q36114402-B6E34510-F852-4829-8283-D49350C9E309Q36153174-23979084-59DE-4EFD-BCDA-5D4F51BC01B8Q36161292-84FA7952-CB45-48F7-AAAF-AB687AE72757Q36170092-5D15F45E-1EC5-4314-AEE2-576309F7C8D0Q36190027-8E23603D-5B0B-4695-A1DE-713D21003274Q36214176-06589822-6358-4271-859A-75AFE85D6ED0Q36250826-5F1AD626-DF41-41C5-A532-7335C3FEC732Q36328468-DD8C3483-26CD-416B-92DE-397150D583A6Q36471074-4C98CB81-FED8-4FB9-B540-5CAB19F45493Q36618025-82A89775-86B9-4722-94A5-B8AD07F074A2
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Eastell R
@ast
Eastell R
@es
Eastell R
@nl
Richard Eastell
@en
type
label
Eastell R
@ast
Eastell R
@es
Eastell R
@nl
Richard Eastell
@en
altLabel
Eastell R
@en
prefLabel
Eastell R
@ast
Eastell R
@es
Eastell R
@nl
Richard Eastell
@en
P31
P496
0000-0002-0323-3366